1. Home
  2. TSHA vs VET Comparison

TSHA vs VET Comparison

Compare TSHA & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$4.38

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Vermilion Energy Inc.

VET

Vermilion Energy Inc.

HOLD

Current Price

$11.76

Market Cap

1.7B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSHA
VET
Founded
2019
1994
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2020
2004

Fundamental Metrics

Financial Performance
Metric
TSHA
VET
Price
$4.38
$11.76
Analyst Decision
Strong Buy
Buy
Analyst Count
13
7
Target Price
$13.00
★ $14.79
AVG Volume (30 Days)
★ 3.2M
1.1M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
N/A
★ 3.31%
EPS Growth
★ 5.56
N/A
EPS
N/A
★ N/A
Revenue
★ $9,773,000.00
N/A
Revenue This Year
N/A
$22.90
Revenue Next Year
$1,023.00
$8.02
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 17.28
N/A
52 Week Low
$3.69
$7.10
52 Week High
$7.30
$14.82

Technical Indicators

Market Signals
Indicator
TSHA
VET
Relative Strength Index (RSI) 29.00 45.46
Support Level $4.37 $11.14
Resistance Level $4.72 $11.93
Average True Range (ATR) 0.26 0.38
MACD -0.02 -0.13
Stochastic Oscillator 1.38 24.64

Price Performance

Historical Comparison
TSHA
VET

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

About VET Vermilion Energy Inc.

Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.

Share on Social Networks: